Essential Resources
Provider Information
Patient Information
From Our Sponsors
Atopic Dermatology Quiz Challenge
Test your knowledge of atopic dermatitis with this quiz and enter for a chance to win a $500 amazon gift card. Show your smarts about pathophysiology, treatments like PDE4 inhibitors, and management strategies
Arcutis Begins Study of Roflumilast Cream 0.05% in Infants with Atopic Dermatitis
Arcutis Biotherapeutics announced today the enrollment of the first patient in the phase 2 INTEGUMENT-INFANT trial.
Atopic Dermatitis Treatment: What Matters Most to Children, Adolescents, Young Adults, and Caregivers?
Treatment goals for atopic dermatitis among youth are diverse, emphasizing the need for tailored approaches based on age and disease severity, a new study suggests.
Roflumilast Topical Foam 0.3% Approved to Treat Plaque Psoriasis in People Aged 12 Years and Older
Itch relief in clinical trials was rapid with the nonsteroidal foam; it is applied once daily with no limitations on body area or duration of use.
Atopic Dermatitis Treatment Caution: Long-Term Oral Corticosteroid Use Ups Cardiovascular and Thrombotic Risks
The potential cardiovascular impact of prolonged oral corticosteroid therapy in the AD population observed in this study confirms longstanding cautions.
LEO Pharma Announces Positive Preliminary Phase 2b Findings for Temtokibart in Atopic Dermatitis
The IL-22FA1 antagonist achieved positive outcomes for the primary endpoint based on percentage change in EASI from baseline to week 16 for 3 highest doses, according to LEO.
Advances and Insights in Atopic Dermatitis Management
This comprehensive publication explores the current landscape and emerging therapies in the treatment of atopic dermatitis, with a particular focus on the use of topical phosphodiesterase-4 (PDE4) inhibitors. It includes insights into immune dysregulation in AD, limitations of conventional therapies, and evolving treatment options aimed at improving patient outcomes and adherence.
Millions of US Adults Have Multiple Forms of Eczema, Study Finds
Nearly 1 in 10 US adults have eczema, with 18% experiencing multiple eczema conditions, researchers from the National Eczema Association reported.
Burden of Moderate to Severe Atopic Dermatitis Weighs Heavily on Children and Adolescents: Real-World Analysis
The burden of disease was particularly pronounced among adolescents, including significantly greater impact on quality of life and psychosocial interaction.
The Toll of Atopic Dermatitis is More than Skin Deep: Q & A with Harvard Child Psychologist Jennifer LeBovidge, PhD
Awareness of the psychological burden of eczema is improving, LeBovidge says, but if clinicians don't address mental health, patients and families will suffer in silence.
Does it Itch? Is it Painful? Is it Dry? Dermatoses Symptoms Don't Lie
Raj Chovatiya, MD, PhD, MSCI, actually said symptoms "never" lie so, particularly in patients with skin of color, if skin signs aren't clear, ask about the patient's experience.
In Patients with Skin of Color, Lebrikizumab for Atopic Dermatitis Gets High Marks for Treatment Satisfaction
In individuals with skin of color with AD, lebrikizumab was associated with improved QoL and importantly with high rates of patient-reported treatment satisfaction.
Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use
Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.
Dermatology Therapeutics: Updates for Primary Care from AAD 2025
Research included new findings on topical and systemic treatments for atopic dermatitis, psoriasis, alopecia areata, and other chronic skin disorders.
Early-Onset Atopic Dermatitis Significantly Impacts Psychosocial Development, Wellbeing Throughout Adult Life
The impact of childhood onset AD on adult psychosocial experience is far reaching and profound according to findings from the Scars of Life Survey.
Contact Dermatitis: Expert Insights on First-Line and Emerging Therapies
JiaDe 'Jeff' Yu, MD, discusses first-line therapies, emerging biologics, and the potential of molecular biomarkers for improved diagnosis.
Patient Benefit Index Complements Traditional Psoriasis Outcome Measures, Study Finds
Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.
sNDA for Roflumilast Cream 0.05% for the Treatment of AD in Children Aged 2 to 5 Years Gets FDA Nod
The FDA has set a PDUFA target action date for October 13, 2025, according to Arcutis Biotherapeutics.
Late Breakers in Atopic Dermatitis: Highlights and Previews with Alexandra Golant, MD
From the revolutionary approval of dupilumab to the promise of potential disease modification with OX40 inhibitors, Golant provided a wide-ranging update of the treatment space.
4 Pearls for Managing Atopic Dermatitis
From black tea compresses to effective mind-body interventions for symptom control, Peter Lio, MD, shares 4 pearls for effective AD management.
10 Dermatology Tips for Primary Care
The dermatologic tips offered in this short slide show come from 4 renowned professionals and reflect their subspecialties.
Atopic Dermatitis Treatments Up Close: Biologics, JAK Inhibitors, and Cytokines, Oh My
Atopic dermatitis management will be the topic of a debate over treatment with biologics and JAK inhibitors and in a focused session on the role of IL-13 in the chronic skin disease.
Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data
A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.
When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
